Platelet reactivity in chronic obstructive pyelonephritis: role of adrenaline in the pathogenesis of complications


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Purpose. Evaluation of platelet reactivity and determination of the role of adrenaline in the initiation of the acute inflammatory response and severity of hematuria in patients with chronic obstructive pyelonephritis (Cop). Material and Methods. The study included 42 patients, 13 with remission of cop, and 29 - with cop relapse. All patients were treated with nonsteroidal anti-inflammatory drugs and antibiotics for at least 5-Ю days prior to the date of hospitalization. Platelets were isolated by centrifugation of citrated peripheral blood. Evaluation of platelet aggregation was performed by Chrono-Log Platelet Aggregometer (usa) using agonists (ADP, epinephrine, PAF, serotonin, collagen) in EC50 concentration. Results. In patients with cop relapse, reaction of peripheral blood reflects the presence of acute inflammation in the urinary tract, which provokes more pronounced hematuria than in chronic inflammation, specific to disease remission. The analysis of remission and relapse phases of cop has revealed platelet hyporeactivity on agonists studied. It was found that the potentiation of the stimulating effects of epinephrine and ADP causes an increase in the functional activity of hyporeactive platelets and is aimed to restriction of hematuria, while the interaction of adrenaline and PAF can provide the growing influence of leukocytes to platelets to initiate acute inflammation in cop. Conclusion. The interaction of different agonists in phases of cop remission and relapse can restore the function of hyporeactive platelets, with the adrenaline acts as a modulator in the pathogenetic mechanisms of cop complications.

Full Text

Restricted Access

About the authors

E. F Barinov

Email: barin0v.ef@gmail.com

References

  1. Michelson A.D. Platelets. San Diego, CA: Academic Press., 2006.
  2. Müller F., Mutch N.J., Schenk W.A., Smith S.A., Esterl L., Spronk H.M., Schmidbauer S., Gahl W.A., Morrissey J.H., Renné T. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell. 2009;139(6):1143-1156.
  3. Kaplan Z.S., Jackson S.P. The role of platelets in atherothrombosis. Hematology Am. Soc. Hematol. Educ. Program. 2011:51-61.
  4. Michelson A.D., Newburger P.E. Platelets and leukocytes: aggregate knowledge. Blood. 2007;110(3):794-795.
  5. Granja T., Schad J., Schüssel P., Fischer C., Häberle H., Rosenberger P., Straub A. Using six-colour flow cytometry to analyse the activation and interaction of platelets and leukocytes. A new assay suitable for bench and bedside conditions. Thromb. Res. 2015;136(4):786-796.
  6. Yeaman M.R. Platelets in defense against bacterial pathogens. Cell. Mol. Life Sci. 2010;67(4):525-544.
  7. Морозов Д.А., Морозова О.Л., Захарова Н.Б., Лакомова Д.Ю. Современные принципы диагностики и прогнозирования течения хронического обструктивного пиелонефрита у детей. Урология. 2013;3:68-73.
  8. Aldaqadossi H.A. Stone expulsion rate of small distal ureteric calculi could be predicted with plasma C-reactiveprotein. Urolithiasis. 2013;41(3):235-239.
  9. Kataoka H., Ariyama Y., Deushi M., Osaka M., Nitta K., Yoshida M. Inhibitory Effect of Serotonin Antagonist on Leukocyte-Endothelial Interactions In Vivo and In Vitro. PLoS One. 2016;11(1): e0147929.
  10. Stępniewska J., Dołęgowska B., Chruściana M., Gołembiewska E., Malinowska-Jędraszczyk A., Marchelek-Myśliwiec M., Ciechanowski K. Platelet - derived CD154 antigen in patients with chronic kidney disease. Clin. Biochem. 2016;49(3):243-247.
  11. Gremmel T., Xhelili E., Steiner S., Koppensteiner R., Kopp C.W., Panzer S. Response to antiplatelet therapy and platelet reactivity to thrombin receptor activating peptide-6 in cardiovascular interventions: Differences between peripheral and coronary angioplasty. Atheroscleros. 2014;232(1):119-124.
  12. Auriel E., Regev K., Korczyn A.D. Nonsteroidal anti-inflammatory drugs exposure and the central nervous system. Handb. Clin. Neurol. 2014;119:577- 584.
  13. Brainard B.M., Epstein K.L., LoBato D.N., Kwon S., Darien B.J., Hurley D.J., Moore J.N. Treatment with aspirin or clopidogrel does not affect equine platelet expression of P selectin or platelet-neutrophil aggregates. Vet. Immunol. Immunopathol. 2012;149(1-2):119-125.
  14. Béres B.J., Tóth-Zsamboki E., Vargova K., Laszló A., Masszi T., Kerecsen G., Préda I., Kiss R.G. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy. Thromb. Haemost. 2008;100(5):829-838.
  15. Offermanns S. Activation of platelet function through G protein-coupled receptors. Circ. Res. 2006;99(1):1293-1304.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies